Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B

Hepatology Research

Volumn 42, Issue 2, 2012, Pages 139-149

  Matsumoto, Akihiro ^a   Tanaka, Eiji ^a   Suzuki, Yoshiyuki ^b   Kobayashi, Mariko ^b   Tanaka, Yasuhito ^d   Shinkai, Noboru ^d   Hige, Shuhei ^f   Yatsuhashi, Hiroshi ^h   Nagaoka, Shinya ^h   Chayama, Kazuaki ⁱ   Tsuge, Masataka ⁱ   Yokosuka, Osamu ^j   Imazeki, Fumio ^j   Nishiguchi, Shuhei ^k   Saito, Masaki ^k   Fujiwara, Kei ^e   Torii, Nobuyuki ^c   Hiramatsu, Naoki ^l   Karino, Yoshiyasu ^g   Kumada, Hiromitsu ^b  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TORANOMON HOSPITAL   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^e NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^f HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g Sapporo Kosei General Hospital   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

ⁱ HIROSHIMA UNIVERSITY   (Japan)

^j CHIBA UNIVERSITY   (Japan)

^k HYOGO COLLEGE OF MEDICINE   (Japan)

^l OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Discontinuation; Hepatitis B core related antigen; Hepatitis B surface antigen; Nucleos(t)ide analogs; Relapse of hepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B ANTIGEN; HEPATITIS B CORE ANTIGEN; HEPATITIS B(E) ANTIGEN; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN DETECTION; ARTICLE; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; RETROSPECTIVE STUDY; RISK ASSESSMENT;

EID: 84863393007     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00910.x     Document Type: Article

References (40)

1. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007; 45: 1056-75.
2. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-39.
3. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-45.
4. Ghany M, Liang TJ. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 2007; 132: 1574-85.
5. Liaw YF, Sung JJ, Chow WC etal. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.
6. Matsumoto A, Tanaka E, Rokuhara A etal. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: a multicenter retrospective study of 2795 patients. Hepatol Res 2005; 32: 173-84.
7. Suzuki Y, Kumada H, Ikeda K etal. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 1999; 30: 743-8.
8. Lok AS, Zoulim F, Locarnini S etal. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 46: 254-65.
9. Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000; 32: 635-9.
10. Honkoop P, de Man RA, Heijtink RA, Schalm SW. Hepatitis B reactivation after lamivudine. Lancet 1995; 346: 1156-7.
11. Chang TT, Gish RG, de Man R etal. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-10.
12. Lai CL, Shouval D, Lok AS etal. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-20.
13. Lai CL, Chien RN, Leung NW etal. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-8.
14. Liu F, Wang L, Li XY etal. Poor durability of lamivudine effectiveness despite stringent cessation criteria: a prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients. J Gastroenterol Hepatol 2011; 26: 456-60.
15. Reijnders JG, Perquin MJ, Zhang N, Hansen BE, Janssen HL. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 2010; 139: 491-8.
16. Liaw YF, Leung N, Kao JH etal. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-83.
17. Leung N. Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues. Hepatol Int 2008; 2: 163-78.
18. Kumada H, Okanoue T, Onji M etal. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan. Hepatol Res 2010; 40: 1-7.
19. Schuttler CG, Wend UC, Faupel FM, Lelie PN, Gerlich WH. Antigenic and physicochemical characterization of the 2nd International Standard for hepatitis B virus surface antigen (HBsAg). J Clin Virol 2010; 47: 238-42.
20. Dai CY, Yu ML, Chen SC etal. Clinical evaluation of the COBAS Amplicor HBV monitor test for measuring serum HBV DNA and comparison with the Quantiplex branched DNA signal amplification assay in Taiwan. J Clin Pathol 2004; 57: 141-5.
21. Ronsin C, Pillet A, Bali C, Denoyel GA. Evaluation of the COBAS AmpliPrep-total nucleic acid isolation-COBAS TaqMan hepatitis B virus (HBV) quantitative test and comparison to the VERSANT HBV DNA 3.0 assay. J Clin Microbiol 2006; 44: 1390-9.
22. Mizokami M, Nakano T, Orito E etal. Hepatitis B virus genotype assignment using restriction fragment length polymorphism patterns. FEBS Lett 1999; 450: 66-71.
23. Kimura T, Rokuhara A, Sakamoto Y etal. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. J Clin Microbiol 2002; 40: 439-45.
24. Suzuki F, Miyakoshi H, Kobayashi M, Kumada H. Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients. J Med Virol 2009; 81: 27-33.
25. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.
26. Gish RG, Lok AS, Chang TT etal. Entecavir therapy for up to 96weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133: 1437-44.
27. Marcellin P. Hepatitis B and hepatitis C in 2009. Liver Int 2009; 29 (Suppl 1): 1-8.
28. Moucari R, Lada O, Marcellin P. Chronic hepatitis B: back to the future with HBsAg. Expert Rev Anti Infect Ther 2009; 7: 633-6.
29. Yokosuka O, Kurosaki M, Imazeki F etal. Management of hepatitis B: consensus of the Japan Society of Hepatology 2009. Hepatol Res 2011; 41: 1-21.
30. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-86.
31. Chen CJ, Yang HI, Su J etal. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
32. Werle-Lapostolle B, Bowden S, Locarnini S etal. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750-8.
33. Sung JJ, Wong ML, Bowden S etal. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005; 128: 1890-7.
34. Wong DK, Tanaka Y, Lai CL, Mizokami M, Fung J, Yuen MF. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. J Clin Microbiol 2007; 45: 3942-7.
35. Brunetto MR, Moriconi F, Bonino F etal. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141-50.
36. Moucari R, Mackiewicz V, Lada O etal. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151-7.
37. Tanaka E, Matsumoto A, Yoshizawa K, Maki N. Hepatitis B core-related antigen assay is useful for monitoring the antiviral effects of nucleoside analogue therapy. Intervirology 2008; 51 (Suppl 1): 3-6.
38. Hosaka T, Suzuki F, Kobayashi M etal. HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy. Liver Int 2010; 30: 1461-70.
39. Matsumoto A, Tanaka E, Minami M etal. Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy. Hepatol Res 2007; 37: 661-6.
40. Shinkai N, Tanaka Y, Orito E etal. Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection. Hepatol Res 2006; 36: 272-6.